AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B

SAN FRANCISCO, March 9, 2023 /PRNewswire/ — Ausper Biopharma Co., Ltd. and AusperBio Therapeutic, Inc. (Together AusperBio) today announced the completion of the first cohort dosing in a Phase 1 clinical trial evaluating AHB–137 in adult healthy volunteers and chronic hepatitis B (CHB)…

Leave a Reply

Your email address will not be published. Required fields are marked *